Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ICP-B208 in advanced solid tumors
CTR20261808Phase 2Active
- Sponsor
- Innovent Biologics
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ICP-B208 in Nonhematologic neoplasms and gastrointestinal stromal tumor (GIST), sponsored by Innovent Biologics. Primary endpoints: Adverse events and serious adverse events, Dose-limiting toxicity and 2 more. Started Jul 2026; status: active.
02
Drugs
ICP-B208
03
Conditions
Nonhematologic neoplasmsgastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on CTR20261808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261808.